MDT-AP-0375
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 48
- os_event
- false
- age_years
- 8
- sex
- M
- new_clusters
- S2
- umap1_2d
- -1.07970767
- umap2_2d
- -9.030565387
- umap1_3d
- -3.798260201
- umap2_3d
- -1.436815606
- umap3_3d
- 5.679312585
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.510
- E2F_TARGETS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- G2M_CHECKPOINT+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.300
- CHOLESTEROL_HOMEOSTASIS+0.280
- MTORC1_SIGNALING+0.270
- OXIDATIVE_PHOSPHORYLATION+0.270
- DNA_REPAIR+0.250
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.290
- HEME_METABOLISM-0.270
- WNT_BETA_CATENIN_SIGNALING-0.130
- IL6_JAK_STAT3_SIGNALING-0.090
- SPERMATOGENESIS-0.090
- ANGIOGENESIS-0.080
- COMPLEMENT-0.080
- PROTEIN_SECRETION-0.070
- INFLAMMATORY_RESPONSE-0.050
- APICAL_SURFACE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0834 | Med | Medulloblastoma | 0.838 |
| 2 | BS_81SP2HX4 | Med | Medulloblastoma | 0.832 |
| 3 | SRR12696771 | — | — | 0.809 |
| 4 | SRR15030865 | — | — | 0.799 |
| 5 | MDT-AP-0549 | Med | Medulloblastoma | 0.797 |
| 6 | BS_R439VVPK | Med | Medulloblastoma | 0.796 |
| 7 | MDT-AP-1381 | Med | Medulloblastoma | 0.793 |
| 8 | 109ABE6B-033D-47E8-A03A-D285BE82C17B | — | — | 0.792 |
| 9 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.788 |
| 10 | MDT-AP-0535 | Med | Medulloblastoma | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |